163 related articles for article (PubMed ID: 1151655)
1. Synthesis of sparsomycin analogs as potential antitumor agents.
Dubois RJ; Lin CC; Michel BL
J Pharm Sci; 1975 May; 64(5):825-9. PubMed ID: 1151655
[TBL] [Abstract][Full Text] [Related]
2. Lipophilic analogues of sparsomycin as strong inhibitors of protein synthesis and tumor growth: a structure-activity relationship study.
van den Broek LA; Lázaro E; Zylicz Z; Fennis PJ; Missler FA; Lelieveld P; Garzotto M; Wagener DJ; Ballesta JP; Ottenheijm HC
J Med Chem; 1989 Aug; 32(8):2002-15. PubMed ID: 2754719
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of sparsomycin and its analogues. Octylsparsomycin: the first analogue more active than sparsomycin.
Liskamp RM; Colstee JH; Ottenheijm HC; Lelieveld P; Akkerman W
J Med Chem; 1984 Mar; 27(3):301-6. PubMed ID: 6699875
[TBL] [Abstract][Full Text] [Related]
4. In vivo antitumor activity of sparsomycin and its analogues in eight murine tumor models.
Zylicz Z; Wagener DJ; van Rennes H; van der Kleijn E; Lelieveld P; van den Broek LA; Ottenheijm HC
Invest New Drugs; 1988 Dec; 6(4):285-92. PubMed ID: 3229941
[TBL] [Abstract][Full Text] [Related]
5. Sparsomycin analogs. IV. Synthesis and antitumor activity of pyrimidine-5-carboxamides and (E)-beta-(pyrimidin-5-yl)acrylamides.
Kanatomo S; Wada A; Yomei M; Hase T; Nagai S; Fukuda S; Tanaka M; Sasaki T
Chem Pharm Bull (Tokyo); 1988 Jun; 36(6):2042-9. PubMed ID: 3240439
[No Abstract] [Full Text] [Related]
6. Synthesis and biological evaluation of sparsomycin analogues.
Duke SS; Boots MR
J Med Chem; 1983 Nov; 26(11):1556-61. PubMed ID: 6415284
[TBL] [Abstract][Full Text] [Related]
7. Pyrimidinylpropenamides as antitumor agents. Analogues of the antibiotic sparsomycin.
Lin CC; Dubois RJ
J Med Chem; 1977 Mar; 20(3):337-41. PubMed ID: 845865
[TBL] [Abstract][Full Text] [Related]
8. Antineoplastic agents. 36. Acetylenic carrier groups.
Pettit GR; Saldana EI
J Med Chem; 1974 Aug; 17(8):896-8. PubMed ID: 4845382
[No Abstract] [Full Text] [Related]
9. Potentiation of cisplatin antitumor activity on L1210 leukemia s.c. by sparsomycin and three of its analogues.
Zylicz Z; Hofs HP; Wagener DJ
Cancer Lett; 1989 Jul; 46(2):153-7. PubMed ID: 2752385
[TBL] [Abstract][Full Text] [Related]
10. Potential anticancer agents. 4. Schiff bases from benzaldehyde nitrogen mustards.
Shekawat DR; Sabnis SS; Deliwala CV
J Med Chem; 1972 Nov; 15(11):1196-7. PubMed ID: 4654676
[No Abstract] [Full Text] [Related]
11. Schedule-dependent enhancement of antitumor activity of ethyldeshydroxy-sparsomycin in combination with classical antineoplastic agents.
Hofs HP; Wagener DJ; de Valk-Bakker V; van Rennes H; de Vos D; Doesburg WH; Ottenheijm HC; de Grip WJ
Anticancer Drugs; 1995 Apr; 6(2):277-84. PubMed ID: 7795276
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the antitumor activity of rifamycin SV.
Adamson RH
Arch Int Pharmacodyn Ther; 1971 Jul; 192(1):61-5. PubMed ID: 5093193
[No Abstract] [Full Text] [Related]
13. Preparation of 4-(p-(bis(2-chloroethyl)amino)phenyl)butyramides as potential antitumor agents. I.
Billman JH; Roehrig GR
J Pharm Sci; 1974 Sep; 63(9):1487-9. PubMed ID: 4427280
[No Abstract] [Full Text] [Related]
14. Sparsomycin analogs. V. Synthesis and antitumor activity of (E)-beta-(pyrimidin-5-yl)acrylamides.
Kanatomo S; Wada A; Hamaoka Y; Nagai S; Fukuda S; Tanaka M; Sasaki T
Chem Pharm Bull (Tokyo); 1988 Nov; 36(11):4421-5. PubMed ID: 3246010
[No Abstract] [Full Text] [Related]
15. Structure-activity relationships of ethylenimines. 8. Optically active methyl-substituted ethylenimines.
Bottini AT; Dev V; Dowden BF; Gandolfi AJ
J Med Chem; 1969 Mar; 12(2):332-3. PubMed ID: 5783614
[No Abstract] [Full Text] [Related]
16. Sparsomycin analogs. VI. Synthesis and antitumor activity of octylsparsomycin analogs.
Kanatomo S; Hase T; Wada A; Ohki K; Nagai S; Tanaka M; Sasaki T
Chem Pharm Bull (Tokyo); 1989 Mar; 37(3):688-91. PubMed ID: 2752478
[TBL] [Abstract][Full Text] [Related]
17. In vivo potentiation of cis-diamminedichloroplatinum (II) antitumor activity by pretreatment with sparsomycin.
Zylicz Z; Wagener DJ; van Rennes H; Wessels JM; van der Kleijn E; de Grip WJ; Ottenheijm HC; van den Broek LA
Cancer Lett; 1986 Jul; 32(1):53-9. PubMed ID: 3742487
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo anticancer activity of mitozolomide and sparsomycin in human tumor xenografts, murine tumors and human bone marrow.
Fiebig HH; Berger DP; Köpping K; Ottenheijm HC; Zylicz Z
J Cancer Res Clin Oncol; 1990; 116(6):550-6. PubMed ID: 2254373
[TBL] [Abstract][Full Text] [Related]
19. Further evaluation of the antitumor activity of homofolate and its reduced derivatives against methotrexate-insensitive tumors.
Mishra LC; Mead JA
Chemotherapy; 1972; 17(4):283-92. PubMed ID: 4504773
[No Abstract] [Full Text] [Related]
20. Potentiation of cisplatin antitumour activity by Ethyldeshydroxy-Sparsomycin in L1210 leukemia.
Hofs HP; Wagener DJ; De Valk-Bakker V; Van Rennes H; Van Zeist AJ; Van Den Broek LA; Ottenheijm HC
Anticancer Res; 1992; 12(1):167-70. PubMed ID: 1567164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
